管理与酒精有关的肝脏疾病中的酒精使用障碍
Mashal Khan1, Sahil Anand1, Akhil Shenoy2
1Department of Psychiatry, NewYork Presbyterian- Weill Cornell Medicine, New York, NY, USA.
Clinics in liver disease
|November 20, 2025
概括
本综述涵盖了管理酒精使用障碍 (AUD) 以及与酒精相关的肝病 (ALD). 它强调查,FDA批准和非标签药物,以及恢复和并发症管理的非药物支持.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 成 药物 药物 药物 药物
- 临床药理学 临床药理学
背景情况:
- 酒精使用障碍 (AUD) 经常与与酒精相关的肝病 (ALD) 一起发生.
- 有效的管理需要同时解决这两种情况.
- 综合护理模式对于患者的治疗结果至关重要.
研究的目的:
- 审查当前在ALD患者中管理AUD的策略.
- 突出药物治疗和非药物干预的作用.
- 强调查和综合治疗方法的重要性.
主要方法:
- 关于AUD和ALD管理的综合文献综述.
- 对AUD和ALD的FDA批准和非标签药物治疗方法的分析.
- 评估非药物干预措施,包括互助小组和数字工具.
主要成果:
- 在ALD患者中,各种查工具对AUD检测有效.
- 药物治疗,无论是FDA批准的还是非标签的,都在管理AUD和ALD方面发挥着作用.
- 非药物干预,如匿名酒者和同行支持,对于长期康复至关重要.
结论:
- 综合管理AUD和ALD对于改善患者预后至关重要.
- 结合药物治疗和心理社会支持的多模式方法优化了治疗.
- 对新型数字工具和治疗策略的持续研究是有必要的.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
204
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
204
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241
Esophageal Varices-II: Clinical Features and Management
349
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
349
Atherosclerosis III: Management
301
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
301
Chronic Pancreatitis II: Collaborative Care
296
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
296


